Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus
- 주제(기타) Multidisciplinary Sciences
- 설명문(일반) [Lee, Kyuhyun; Lee, Soo Kyoung; Lee, Juyeon] Ewha Womans Univ, Coll Med, Seoul, South Korea; [Jeon, Bo Kyung; Kim, Dong Hyeok; Park, Junbeom] Ewha Womans Univ, Med Ctr, Dept Cardiol, Seoul, South Korea; [Kim, Tae-Hoon; Yu, Hee Tae; Joung, Boyoung; Lee, Moon-Hyoung; Pak, Hui-Nam] Yonsei Univ Hlth Syst, Seoul, South Korea; [Lee, Jung Myung] Kyung Hee Univ, Med Ctr, Seoul, South Korea; [Park, Jin-Kyu] Hanyang Univ, Seoul Hosp, Dept Cardiol, Seoul, South Korea; [Baek, Yong-Soo] Inha Univ, Med Inha Univ Hosp, Coll Med, Incheon, South Korea; [Shim, Jaemin] Korea Univ, Anam Hosp, Coll Med, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 PUBLIC LIBRARY SCIENCE
- 발행년도 2023
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000204320
- 본문언어 영어
- Published As https://doi.org/10.1371/journal.pone.0280359
초록/요약
SGLT-2 inhibitor, traditionally used for glycemic control, has several beneficial effects that can help manage heart failure (HF). SGLT-2 inhibitors reduce the risk of cardiovascular mortality in patients with HF. As atrial fibrillation (AF) is closely associated with HF and diabetes mellitus (DM) is a risk factor for AF, we assume that SGLT-2 inhibitors will also show therapeutic benefits regarding AF, especially for rhythm control. This trial has a multicenter, prospective, open, blinded endpoint design. It is a 1:1 randomized and controlled study. A total of 716 patients who are newly diagnosed of AF and DM within 1 year will be enrolled from 7 tertiary medical centers. The trial is designed to compare the effects of SGLT-2 inhibitors and other oral hypoglycemic agents on atrial rhythm control in patients with AF and DM. The primary outcome is the recurrence of AF within a year (including post-antiarrhythmic drugs (AAD) or ablation). The secondary outcomes are the ablation rate within a year, change in AF burden, size of the left atrium, NT-proBNP, the AF symptom score, and the quality of life. This trial will prospectively evaluate the effect and safety of SGLT-2 inhibitors on AF rhythm control in patients with DM. It will provide an invaluable dataset on rhythm control in AF with DM for future studies and offer novel information to assist in clinical decisions. (BEYOND trial, ClinicalTrials.gov number: NCT05029115. https://clinicaltrials.gov/ct2/show/NCT05029115).
more